share_log

中泰证券4月8日发布研报称，给予复星医药（600196.SH）买入评级。评级理由主要包括：1）医药工业维持稳健，创新投入保持稳健；2）器械诊断、医疗服务占比维持25%-30%；3）在研品种进展顺利，创新转型进行时。（每日经济新闻）

Zhongtai Securities released a research report on April 8 stating that it gave Fosun Pharmaceuticals (600196.SH) a purchase rating. The main reasons for the rating include: 1) the pharmaceutical industry remains steady, and investment in innovation remain

Zhitong Finance ·  Apr 9 10:01
Zhongtai Securities released a research report on April 8 stating that it gave Fosun Pharmaceuticals (600196.SH) a purchase rating. The main reasons for the rating include: 1) the pharmaceutical industry remains steady, and investment in innovation remains steady; 2) maintaining 25%-30% share of device diagnosis and medical services; 3) when the types of research progressed smoothly and innovation and transformation were underway. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment